Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration

Retina. 2008 Jun;28(6):789-93. doi: 10.1097/IAE.0b013e31817082d7.

Abstract

Purpose: To evaluate combination treatment with reduced-fluence photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVT) injection for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).

Methods: This is a retrospective consecutive case series of 23 previously untreated eyes of 22 patients with subfoveal CNV secondary to AMD. Six eyes were treated with 50 J/cm; 8, with 40 J/cm; and 9, with 25 J/cm. PDT was immediately followed by a 4-mg IVT injection. Patients were observed for 6 months at 6-week intervals.

Results: : The 50 J/cm subset lost a mean of 2.2 lines of Snellen visual acuity at the 6-month follow-up compared with a 1-line lost in the 40 J/cm subset and a 0.9-line gain in the 25 J/cm subset. In the 50 J/cm subset, 60% lost < or =3 lines of Snellen visual acuity, 33% gained > or =0 line, and 33% gained > or =3 lines. In the 40 J/cm subset, 75% lost < or =3 lines of Snellen visual acuity, 50% gained > or =0 line, and 25% gained > or =3 lines. In the 25 J/cm subset, 89% lost < or =3 lines of Snellen visual acuity, 56% gained > or =0 line, and 33% gained > or =3 lines. Fifty percent of the 50 J/cm subset, 50% of the 40 J/cm subset, and 33% of the 25 J/cm subset required retreatment by 6 months.

Conclusion: Although the sample in this study was small, there was a dose-response trend toward better visual outcomes and fewer treatments in the group treated with IVT injection and reduced-fluence PDT. This study along with other previously reported work suggests that studies using PDT in combination treatment for CNV should consider adding a reduced-fluence PDT arm.

MeSH terms

  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Glucocorticoids / administration & dosage*
  • Humans
  • Injections
  • Macular Degeneration / complications*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Retrospective Studies
  • Treatment Outcome
  • Triamcinolone Acetonide / administration & dosage*
  • Verteporfin
  • Visual Acuity
  • Vitreous Body

Substances

  • Glucocorticoids
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
  • Triamcinolone Acetonide